Literature DB >> 9373321

Affinity maturation of recombinant antibodies using E. coli mutator cells.

R A Irving1, A A Kortt, P J Hudson.   

Abstract

BACKGROUND: Phage libraries can display repertoires of antibodies which are greater in number than the mammalian immune response. However, the selected antibodies often have low binding affinity to their target antigen or hapten (KD below 10(-6) M), which is characteristic of the primary immune repertoire. There is a need for procedures to mimic somatic hypermutation through antigen driven affinity maturation, thereby increasing the affinity of selected immunoglobulins.
OBJECTIVE: To investigate the effectiveness of mutation and affinity selection of recombinant antibody genes with mutator E. coli cells, incorporating phage-display strategies. STUDY
DESIGN: Unique human scFvs were selected from a naive Fd-phage library. These genes were mutated by propagation in mutD5 mutator E. coli cells (mutD5-FIT) which were competent for Fd (M13) based phagemid transfections and generated point mutations (transversions and transitions) in the scFv genes. Individual phage-displayed scFvs were affinity selected from the mutation library and were assayed as soluble scFvs by ELISA and BIAcore for binding to antigen.
RESULTS: The in vivo mutation of phage-displayed scFvs in E. coli mutD5-FIT, combined with affinity selection against antigen, produced scFv molecules with improved binding activity. The point mutations which resulted in single amino acid substitutions frequently produced ten fold increases in apparent binding affinity. Structural comparisons revealed that these point mutations were in framework regions (adjacent to the CDRs) and within the CDRs. In one case the apparent affinity of an anti-glycophorin scFv after mutation in the VL framework region close to CDR3 increased by 10(3). However, this increase in apparent affinity was accompanied by an increased propensity to dimerise and form aggregates.
CONCLUSIONS: A strategy for the rapid affinity maturation of scFv and Fab antibody fragments has been developed which utilises mutator strains of E. coli and incorporates phage display of antibody repertoires (libraries).

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 9373321     DOI: 10.1016/1380-2933(96)00044-9

Source DB:  PubMed          Journal:  Immunotechnology        ISSN: 1380-2933


  6 in total

Review 1.  Engineering the variable region of therapeutic IgG antibodies.

Authors:  Tomoyuki Igawa; Hiroyuki Tsunoda; Taichi Kuramochi; Zenjiro Sampei; Shinya Ishii; Kunihiro Hattori
Journal:  MAbs       Date:  2011-05-01       Impact factor: 5.857

2.  Rise and fall of an anti-MUC1 specific antibody.

Authors:  Holger Thie; Lars Toleikis; Jiandong Li; Reinhard von Wasielewski; Gunther Bastert; Thomas Schirrmann; Isabel Tourais Esteves; Christian K Behrens; Bénédict Fournes; Nathalie Fournier; Christophe de Romeuf; Michael Hust; Stefan Dübel
Journal:  PLoS One       Date:  2011-01-14       Impact factor: 3.240

3.  Effective Optimization of Antibody Affinity by Phage Display Integrated with High-Throughput DNA Synthesis and Sequencing Technologies.

Authors:  Dongmei Hu; Siyi Hu; Wen Wan; Man Xu; Ruikai Du; Wei Zhao; Xiaolian Gao; Jing Liu; Haiyan Liu; Jiong Hong
Journal:  PLoS One       Date:  2015-06-05       Impact factor: 3.240

4.  In vivo diversification of target genomic sites using processive base deaminase fusions blocked by dCas9.

Authors:  Beatriz Álvarez; Mario Mencía; Víctor de Lorenzo; Luis Ángel Fernández
Journal:  Nat Commun       Date:  2020-12-22       Impact factor: 14.919

Review 5.  Phage display-based strategies for cloning and optimization of monoclonal antibodies directed against human pathogens.

Authors:  Nicola Clementi; Nicasio Mancini; Laura Solforosi; Matteo Castelli; Massimo Clementi; Roberto Burioni
Journal:  Int J Mol Sci       Date:  2012-07-04       Impact factor: 6.208

6.  The influence of antibody fragment format on phage display based affinity maturation of IgG.

Authors:  Miriam Steinwand; Patrick Droste; André Frenzel; Michael Hust; Stefan Dübel; Thomas Schirrmann
Journal:  MAbs       Date:  2014 Jan-Feb       Impact factor: 5.857

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.